Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Beinborn

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal of Medicinal Chemistry|March 8, 2024
A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP AnaloguesKathleen M Sicinski, Damla Sürmeli, Jasper Du, et al.
Molecular Pharmacology|August 13, 2010
The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugsJean-Philippe Fortin, Lei Ci, Jonathan Schroeder, et al.
Endocrinology|October 13, 2009
Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesityOlga V Danilova, Albert K Tai, Deanna A Mele, et al.
ACS Central Science|April 1, 2021
A Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide LigandsKathleen M Sicinski, Vittorio Montanari, Venkata S Raman, et al.
Journal of Medicinal Chemistry|September 19, 2013
A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substratesKathryn R Heard, Wengen Wu, Youhua Li, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal of Medicinal Chemistry|March 8, 2024
A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP AnaloguesKathleen M Sicinski, Damla Sürmeli, Jasper Du, et al.
Molecular Pharmacology|August 13, 2010
The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugsJean-Philippe Fortin, Lei Ci, Jonathan Schroeder, et al.
Endocrinology|October 13, 2009
Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesityOlga V Danilova, Albert K Tai, Deanna A Mele, et al.
ACS Central Science|April 1, 2021
A Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide LigandsKathleen M Sicinski, Vittorio Montanari, Venkata S Raman, et al.
Journal of Medicinal Chemistry|September 19, 2013
A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substratesKathryn R Heard, Wengen Wu, Youhua Li, et al.
Pageof 4